RICTOR polymorphisms Affect Efficiency of Platinum-Based Chemotherapy in Chinese Non-Small-Cell Lung Cancer Patients

References

• Torre LA , BrayF , SiegelRLet al. Global cancer statistics, 2012 . CA Cancer J. Clin.65 ( 2 ), 87 – 108 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Reck M , HeigenerDF , MokTet al. Management of non-small-cell lung cancer: recent developments . Lancet382 ( 9893 ), 709 – 719 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Masters GA , TeminS , AzzoliCGet al. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline update . J. Clin. Oncol.33 ( 30 ), 3488 – 3515 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Azzoli CG , BakerSJr , TeminSet al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer . J. Clin. Oncol.27 ( 36 ), 6251 – 6266 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Schiller JH , HarringtonD , BelaniCPet al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer . N. Engl. J. Med.346 ( 2 ), 92 – 98 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Goffin J , LacchettiC , EllisPMet al. Lung Cancer Disease Site Group of Cancer Care Ontario’s Program in evidence-based C. First-line systemic chemotherapy in the treatment of advanced non-small-cell lung cancer: a systematic review . J. Thorac. Oncol.5 ( 2 ), 260 – 274 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Wu W , LiH , WangHet al. Effect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese non-small-cell lung cancer patients . PLoS ONE7 ( 3 ), e33200 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Li X , ShaoM , WangSet al. Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small-cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy . Tumour Biol.35 ( 11 ), 11159 – 11170 ( 2014 ).
   PubMedGoogle Scholar
• Shiraishi K , KohnoT , TanaiCet al. Association of DNA repair gene polymorphisms with response to platinum-based doublet chemotherapy in patients with non-small-cell lung cancer . J. Clin. Oncol.28 ( 33 ), 4945 – 4952 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Ludovini V , FlorianiI , PistolaLet al. Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small-cell lung cancer patients . J. Thorac. Oncol.6 ( 12 ), 2018 – 2026 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Qian J , GuS , WuQet al. Association of CASP7 polymorphisms and survival of patients with non-small-cell lung cancer with platinum-based chemotherapy treatment . Chest142 ( 3 ), 680 – 689 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Qian J , QuHQ , YangLet al. Association between CASP8 and CASP10 polymorphisms and toxicity outcomes with platinum-based chemotherapy in Chinese patients with non-small-cell lung cancer . Oncologist17 ( 12 ), 1551 – 1561 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Han B , GaoG , WuWet al. Association of ABCC2 polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small-cell lung cancer patients . Lung cancer72 ( 2 ), 238 – 243 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Laplante M , SabatiniDM . mTOR signaling in growth control and disease . Cell149 ( 2 ), 274 – 293 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Inoki K , GuanKL . Complexity of the TOR signaling network . Trends Cell Biol.16 ( 4 ), 206 – 212 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Hoeffer CA , KlannE . mTOR signaling: at the crossroads of plasticity, memory and disease . Trends Neurosci.33 ( 2 ), 67 – 75 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Gulhati P , BowenKA , LiuJet al. mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways . Cancer Res.71 ( 9 ), 3246 – 3256 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Sarbassov DD , AliSM , KimDHet al. RICTOR, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton . Curr. Biol.14 ( 14 ), 1296 – 1302 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Ikenoue T , InokiK , YangQet al. Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling . EMBO J.27 ( 14 ), 1919 – 1931 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Wu MJ , ChangCH , ChiuYTet al. RICTOR-dependent AKT activation and inhibition of urothelial carcinoma by rapamycin . Urol. Oncol.30 ( 1 ), 69 – 77 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Hay N . The Akt-mTOR tango and its relevance to cancer . Cancer cell8 ( 3 ), 179 – 183 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Sarbassov DD , GuertinDA , AliSMet al. Phosphorylation and regulation of Akt/PKB by the RICTOR–mTOR complex . Science307 ( 5712 ), 1098 – 1101 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Al Sawah E , ChenX , MarchionDCet al. Perifosine, an AKT inhibitor, modulates ovarian cancer cell line sensitivity to cisplatin-induced growth arrest . Gynecol. Oncol.131 ( 1 ), 207 – 212 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Brognard J , ClarkAS , NiYet al. Akt/protein kinase B is constitutively active in non-small-cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation . Cancer Res.61 ( 10 ), 3986 – 3997 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• David O , JettJ , LebeauHet al. Phospho-Akt overexpression in non-small-cell lung cancer confers significant stage-independent survival disadvantage . Clin. Cancer Res.10 ( 20 ), 6865 – 6871 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Das G , ShirasA , ShanmuganandamKet al. RICTOR regulates MMP-9 activity and invasion through Raf-1–MEK–ERK signaling pathway in glioma cells . Mol. Carcinog.50 ( 6 ), 412 – 423 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Carr TD , FeehanRP , HallMNet al. Conditional disruption of rictor demonstrates a direct requirement for mTORC2 in skin tumor development and continued growth of established tumors . Carcinogenesis36 ( 4 ), 487 – 497 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Pan SJ , ZhanSK , PanYXet al. Tetraspanin 8-rictor-integrin alpha3 complex is required for glioma cell migration . Int. J. Mol. Sci.16 ( 3 ), 5363 – 5374 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Sun B , ChenL , FuHet al. Upregulation of RICTOR gene transcription by the proinflammatory cytokines through NF-kappaB pathway contributes to the metastasis of renal cell carcinoma . Tumour Biol.37 ( 4 ), 4457 – 4466 ( 2016 ).
   PubMedGoogle Scholar
• Zhang F , ZhangX , LiMet al. mTOR complex component Rictor interacts with PKCzeta and regulates cancer cell metastasis . Cancer Res.70 ( 22 ), 9360 – 9370 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Li J , XuZ , JiangLet al. RICTOR/mTORC2 protects against cisplatin-induced tubular cell death and acute kidney injury . Kidney Int.86 ( 1 ), 86 – 102 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Im-Aram A , FarrandL , BaeSMet al. The mTORC2 component RICTOR contributes to cisplatin resistance in human ovarian cancer cells . PLoS ONE8 ( 9 ), e75455 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Zhao X , WangX , WuWet al. Matrix metalloproteinase-2 polymorphisms and clinical outcome of Chinese patients with non-small-cell lung cancer treated with first-line, platinum-based chemotherapy . Cancer118 ( 14 ), 3587 – 3598 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Therasse P , ArbuckSG , EisenhauerEAet al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada . J. Natl Cancer Inst.92 ( 3 ), 205 – 216 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Barrett JC , FryB , MallerJ , DalyMJ . Haploview: analysis and visualization of LD and haplotype maps . Bioinformatics21 ( 2 ), 263 – 265 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Yang Q , GuanKL . Expanding mTOR signaling . Cell Res.17 ( 8 ), 666 – 681 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Guertin DA , SabatiniDM . Defining the role of mTOR in cancer . Cancer Cell12 ( 1 ), 9 – 22 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Bashir T , CloningerC , ArtinianNet al. Conditional astroglial RICTOR overexpression induces malignant glioma in mice . PLoS ONE7 ( 10 ), e47741 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Mcdonald PC , OloumiA , MillsJet al. RICTOR and integrin-linked kinase interact and regulate Akt phosphorylation and cancer cell survival . Cancer Res.68 ( 6 ), 1618 – 1624 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Bian YH , WangZS , XuJet al. Elevated Rictor expression is associated with tumor progression and poor prognosis in patients with gastric cancer . Biochem. Biophys. Res. Commun.464 ( 2 ), 534 – 540 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Masri J , BernathA , MartinJet al. mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor . Cancer Res.67 ( 24 ), 11712 – 11720 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Cui Y , ZhaoJ , YiLet al. microRNA-153 targets mTORC2 component RICTOR to inhibit glioma cells . PLoS ONE11 ( 6 ), e0156915 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Micevic G , MuthusamyV , DamskyWet al. DNMT3b modulates melanoma growth by controlling levels of mTORC2 component RICTOR . Cell Rep.14 ( 9 ), 2180 – 2192 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Stewart DJ . Mechanisms of resistance to cisplatin and carboplatin . Crit. Rev. Oncol. Hematol.63 ( 1 ), 12 – 31 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Tanaka K , BabicI , NathansonDet al. Oncogenic EGFR signaling activates an mTORC2–NF-kappaB pathway that promotes chemotherapy resistance . Cancer discov.1 ( 6 ), 524 – 538 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Zheng G , JiaX , PengCet al. The miR-491-3p/mTORC2/FOXO1 regulatory loop modulates chemo-sensitivity in human tongue cancer . Oncotarget6 ( 9 ), 6931 – 6943 ( 2015 ).
   PubMedGoogle Scholar
• Shuhua W , ChenboS , YangyangLet al. Autophagy-related genes Raptor, RICTOR, and Beclin1 expression and relationship with multidrug resistance in colorectal carcinoma . Hum. Pathol.46 ( 11 ), 1752 – 1759 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Masui K , TanakaK , IkegamiSet al. Glucose-dependent acetylation of RICTOR promotes targeted cancer therapy resistance . Proc. Natl Acad. Sci. USA112 ( 30 ), 9406 – 9411 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Foster H , ColeyHM , GoumenouAet al. Differential expression of mTOR signalling components in drug resistance in ovarian cancer . Anticancer Res.30 ( 9 ), 3529 – 3534 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Yang SX , CostantinoJP , KimCet al. Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer . J. Clin. Oncol.28 ( 18 ), 2974 – 2981 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Polak R , BuitenhuisM . The PI3K/PKB signaling module as key regulator of hematopoiesis: implications for therapeutic strategies in leukemia . Blood119 ( 4 ), 911 – 923 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Lee D , SykesSM , KalaitzidisDet al. Transmembrane inhibitor of RICTOR/mTORC2 in hematopoietic progenitors . Stem Cell Reports3 ( 5 ), 832 – 840 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• He Y , LiD , CookSLet al. Mammalian target of rapamycin and RICTOR control neutrophil chemotaxis by regulating Rac/Cdc42 activity and the actin cytoskeleton . Mol. Biol. Cell24 ( 21 ), 3369 – 3380 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Yamada O , OzakiK , NakatakeMet al. Akt and PKC are involved not only in upregulation of telomerase activity but also in cell differentiation-related function via mTORC2 in leukemia cells . Histochem. Cell Biol.134 ( 6 ), 555 – 563 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Magee JA , IkenoueT , NakadaDet al. Temporal changes in PTEN and mTORC2 regulation of hematopoietic stem cell self-renewal and leukemia suppression . Cell Stem Cell11 ( 3 ), 415 – 428 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Khan SG , Muniz-MedinaV , ShahlaviTet al. The human XPC DNA repair gene: arrangement, splice site information content and influence of a single nucleotide polymorphism in a splice acceptor site on alternative splicing and function . Nucleic Acids Res.30 ( 16 ), 3624 – 3631 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Van Kuilenburg AB , MeijerJ , MulANet al. Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity . Hum. Genet.128 ( 5 ), 529 – 538 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Xiong L , CatoireH , DionPet al. MEIS1 intronic risk haplotype associated with restless legs syndrome affects its mRNA and protein expression levels . Hum. Mol. Genet.18 ( 6 ), 1065 – 1074 ( 2009 ).
   PubMed Web of Science ®Google Scholar